

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PAPER

09/11/2007

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 9301-123 09/724,538 11/28/2000 7044 Daniel D. Shoemaker 20583 09/11/2007 EXAMINER **JONES DAY 222 EAST 41ST ST** LU, FRANK WEI MIN NEW YORK, NY 10017 ART UNIT PAPER NUMBER 1634 MAIL DATE **DELIVERY MODE**

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•	Application	ı No.	Applicant(s)
Office Action Summary	09/724,538		SHOEMAKER ET AL.
	Examiner		Art Unit
	Frank W Lu	, l	1634
The MAILING DATE of this communication appears on the cover sheet with the correspondence address			
Period for Reply			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status			
1) Responsive to communication(s) filed on 19 March 2007			
· ' :: _ :: _ :: :	is action is r		•
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.			
Disposition of Claims			
4) Claim(s) 1,4-34,36,45,46,86-90,157-181,183,212,213,263-267 and 280-296 is/are pending in the application.			
4a) Of the above claim(s) 46,88,212,213,266 and 267 is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6)⊠ Claim(s) <u>1,4-34,36,45,86,87,89,90,157-181,183,263-265 and 280-296</u> is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claim(s) are subject to restriction and/or election requirement.			
Application Papers			
9) The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
11)⊠ The proposed drawing correction filed on <u>01 April 2003</u> is: a)⊠ approved b)☐ disapproved by the Examiner.			
If approved, corrected drawings are required in reply to this Office action.			
12) The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. §§ 119 and 120			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:			
· · · · · · · · · · · · · · · · · · ·			
1. Certified copies of the priority documents have been received.			
 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage 			
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.			
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).			
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s)			
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		-	r (PTO-413) Paper No(s) Patent Application (PTO-152)

Art Unit: 1634

DETAILED ACTION

Response to Amendment

1. Applicant's response to the office action filed on March 19, 2007 has been entered. The claims pending in this application are claims 1, 4-34, 36, 45, 46, 86-90, 157-181, 183, 212, 213, 263-267, and 280-296 wherein claims 46, 88, 212, 213, 266, and 267 have been withdrawn due to species election. Rejection and/or objection not reiterated from the previous office action are hereby withdrawn in view of the response filed on March 19, 2007.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Enablement

Claims 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293-296 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In *In re Wands*, 858 F.2d 731,737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) the court considered the issue of enablement in molecular biology. The Court summarized eight factors to be considered in a determination of "undue experimentation". These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the

Application/Control Number: 09/724,538

Art Unit: 1634

presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the breadth of the claims. The Court also stated that although the level of skill in molecular biology is high, results of experiments in molecular biology are unpredictable.

To begin, there is no direction or guidance in the specification to show that the methods recited in claims 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293-296 can be performed. While the relative skill in the art is very high (the Ph.D. degree with laboratory experience), there is no predictability whether 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293-296 can be performed.

First, claims 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293 296 are directed to a method for analyzing exon expression in a cell sample. Although it is known that real-time RT-PCR (see Saegusa *et al.*, (Jpn. J. Cancer Res., 89, 291-298, 1998) and nucleic acid arrays can be used to measure expression levels of a plurality of different individual exons or different individual multiexons in each of a plurality of different genes in the genome of an organism from which said cell sample is derived, since claims 1, 10, 284, and 285 do not require that each of the plurality of different genes or a sample comprising RNAs or nucleic acids contains different splicing forms, when a gene in the plurality of different genes or RNAs or nucleic acids does not contain different splicing forms, it is unclear how to differentiate the nucleic acid expression level of a whole gene from the nucleic acid expression level of individual exons or individual multiexons of the whole gene using real-time RT-PCR or nucleic acid arrays.

Second, since claim 10 does not require that the polynucleotide probes on the positionally-addressable array contains probes which hybridize to different splicing forms of the

Application/Control Number: 09/724,538

Art Unit: 1634

at least one gene recited in claim 1, it is unclear how to measuring, *in vitro*, the nucleic acid expression level of each of said plurality of different variants of said exon in said at least one gene as recited in claim 1.

Third, although claims 284 and 285 are directed to a method for analyzing exon expression, since there is no method step for analyzing exon expression in the claim, it is unclear how to analyze exon expression.

For the reasons discussed above, it is unpredictable how the methods recited in claims 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293-296 can be performed and it would have required undue experimentation for one skilled in the art at the time of the invention to practice over the full scope of the invention claimed. This is particularly true given the nature of the invention, the state of the prior art, the breadth of the claims, the amount of experimentation necessary, the working examples provided and scarcity of guidance in the specification, and the unpredictable nature of the art. The undue experimentation at least includes to test whether the methods recited in claims 1, 4-34, 36, 45, 86, 87, 89, 90, 157-181, 183, 263-265, 280-283, and 293-296 can be performed.

Conclusion

4. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Application/Control Number: 09/724,538 Page 5

Art Unit: 1634

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

- 5. No claim is allowed.
- 6. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is (571)273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571)272-0735.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

August 30, 2007

FRANK LU PRIMARY EXAMINER